Cathepsin S as a potential therapeutic target for chronic pain

Costigan, 2009, Neuropathic pain: a maladaptive response of the nervous system to damage, Annu Rev Neurosci, 32, 1, 10.1146/annurev.neuro.051508.135531 Totsch, 2017, Immune system involvement in specific pain conditions, Mol Pain, 13, 10.1177/1744806917724559 Jain, 2020, Unraveling the Plastic Peripheral Neuroimmune Interactome, J Immunol, 204, 257, 10.4049/jimmunol.1900818 Lecaille, 2002, Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design Chem, Rev., 102, 4459 Vasiljeva, 2007, Emerging roles of cysteine cathepsins in disease and their potential as drug targets, Curr Pharm Des, 13, 385, 10.2174/138161207779313542 Quraishi, 2001, Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S. Contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family, J Biol Chem, 276, 8118, 10.1074/jbc.M005851200 Vasiljeva, 2005, Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans, FEBS Lett., 579, 1285, 10.1016/j.febslet.2004.12.093 Shi, 1999, Cathepsin S required for normal MHC class II peptide loading and germinal center development, Immunity, 10, 197, 10.1016/S1074-7613(00)80020-5 Riese, 1998, Cathepsin S activity regulates antigen presentation and immunity, J Clin Invest, 101, 2351, 10.1172/JCI1158 Barclay, 2007, Role of the cysteine protease cathepsin S in neuropathic hyperalgesia, Pain, 130, 225, 10.1016/j.pain.2006.11.017 Clark, 2007, Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain, Proc Natl Acad Sci U S A, 104, 10655, 10.1073/pnas.0610811104 Clark, 2010, Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor, Glia, 58, 1710, 10.1002/glia.21042 Hsing, 2005, The lysosomal cysteine proteases in MHC class II antigen presentation, Immunol Rev, 207, 229, 10.1111/j.0105-2896.2005.00310.x Honey, 2003, Lysosomal cysteine proteases regulate antigen presentation, Nat Rev Immunol, 3, 472, 10.1038/nri1110 Hsieh, 2002, A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation, J Immunol, 168, 2618, 10.4049/jimmunol.168.6.2618 Nakagawa, 1999, Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice, Immunity, 10, 207, 10.1016/S1074-7613(00)80021-7 M. Baugh, D. Black, P. Westwood, E. Kinghorn, K. McGregor, J. Bruin, W. Hamilton, M. Dempster, C. Claxton, J. Cai, J. Bennett, C. Long, H. Mckinnon, P. Vink, L. Hoed, M. Gorecka, K. Vora, E. Grant, D.M. Percival, M.A. Boots, M.-j. van Lierop. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun, 36 (2011), pp. 201–209. O. Irie, T. Kosaka, M. Kishida, J. Sakaki, K. Masuya, K. Konishi, F. Yokokawa, T. Ehara, A. Iwasaki, Y. Iwaki, Y. Hitomi, A. Toyao, H. Gunji, N. Teno, G. Iwasaki, H. Hirao, T. Kanazawa, K. Tanabe, P.C. Hiestand, M. Malcangio, A.J. Fox, S.J. Bevan, M. Yaqoob, A.J. Culshaw, T.W. Hart, A. Hallett. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg. Med. Chem. Lett., 18 (2008), pp. 5280–5284. Petanceska, 1996, Expression of rat cathepsin S in phagocytic cells, J Biol Chem, 271, 4403, 10.1074/jbc.271.8.4403 Liuzzo, 1999, Neurotrophic factors regulate cathepsin S in macrophages and microglia: a role in the degradation of myelin basic protein and amyloid beta peptide, Mol Med, 5, 334, 10.1007/BF03402069 Liuzzo, 1999, Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions, Mol Med, 5, 320, 10.1007/BF03402068 Resier, 2010, adair B and Reinheckel T. Specialised roles for cysteine cathepsins in health and disease, J Clin Invest, 120, 3421, 10.1172/JCI42918 Clark, 2012, Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model, Arthritis Rheum, 64, 2038, 10.1002/art.34351 Edman, 2018, Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren’s Syndrome patients, Sci Rep, 8, 11044M, 10.1038/s41598-018-29411-9 Costigan, K. Befort, L. Karchewski, R.S. Griffin, D. D'Urso, A. Allchorne, J. Sitarski, J.W. Mannion, R.E. Pratt, C.J. Woolf. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci., 3 (2002), p. 16. Yu, 2020, Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain, Nat Commun, 11, 264, 10.1038/s41467-019-13839-2 Nieto, 2016, Neuron-immune mechanisms contribute to pain in early stages of arthritis, J Neuroinflammation, 13, 96, 10.1186/s12974-016-0556-0 Zhang, 2014, Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state, J Neurosci, 34, 3013, 10.1523/JNEUROSCI.3681-13.2014 Lee-Dutra, 2011, Cathepsin S inhibitors: 2004-2010, Expert Opin Ther Pat, 21, 311, 10.1517/13543776.2011.553800 Drake, 2017, Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned, Endocr Rev, 38, 325, 10.1210/er.2015-1114 Galibert, 2018, Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S, Eur J Med Chem, 144, 201, 10.1016/j.ejmech.2017.12.012 Irie, 2008, Allan Hallett. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain, J Med Chem, 51, 5502, 10.1021/jm800839j Hewitt, 2016, Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain, J Pharmacol Exp Ther, 358, 387, 10.1124/jpet.116.232926 Montague-Cardoso, 2020, Changes in vascular permeability in the spinal cord contribute to chemotherapy-induced neuropathic pain, Brain Behav Immun, 83, 248, 10.1016/j.bbi.2019.10.018 Old, 2014, Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain, J Clin Invest, 124, 2023, 10.1172/JCI71389 Clark AK, Yip PK, Malcangio M. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci. 2009;29(21):6945–54.Corcione A., Ferretti E., Bertolotto M. et al CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS ONE( 2009) 4, e8485. Corcione, 2009, CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes, PLoS One, 4, 10.1371/journal.pone.0008485 Auffray, 2007, Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior, Science, 317, 666, 10.1126/science.1142883 Hundhausen, 2003, The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion, Blood., 102, 1186, 10.1182/blood-2002-12-3775 Hurst, 2009, Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment, J Neuroimmunol, 210, 108, 10.1016/j.jneuroim.2009.02.008 Clark, 2012, Microglial signalling mechanisms: Cathepsin S and Fractalkine, Exp Neurol, 234, 283, 10.1016/j.expneurol.2011.09.012 Zhuang, 2007, Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine, Brain Behav Immun, 21, 642, 10.1016/j.bbi.2006.11.003 Lindia, 2005, Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain, J Pain, 6, 434, 10.1016/j.jpain.2005.02.001 Zhao, 2014, Liedtke W5, McIntyre P, Vanner SJ, Korbmacher C, Bunnett NW. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4, J Biol Chem, 289, 27215, 10.1074/jbc.M114.599712 Alessandri-Haber, 2005, TRPV4 mediates pain-related behavior induced by mild hypertonic stimuli in the presence of inflammatory mediator, Pain., 118, 70, 10.1016/j.pain.2005.07.016 Jimenez-Vargas, 2018, Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome, Proc Natl Acad Sci U S A, 115, E7438, 10.1073/pnas.1721891115 Payne, 2014, Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects, Br J Clin Pharmacol, 78, 1334, 10.1111/bcp.12470 Chung, 2019, Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour, Neurobiol Pain, 6, 100032, 10.1016/j.ynpai.2019.100032